<DOC>
	<DOC>NCT01057901</DOC>
	<brief_summary>The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.</brief_summary>
	<brief_title>Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America</brief_title>
	<detailed_description />
	<mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
	<criteria>Inclusion criteria: Naturally postmenopausal women of any age with at least one ovary Diagnosis of Hypoactive Sexual Desire Disorder, generalized acquired type,of at least six months duration Stable, monogamous heterosexual relationship for at least one year Willing to discuss sexual issues Willing to engage in sexual activity at least once a month Normal Pap smear Normal mammogram Normal uterine lining Able to comply with daily use of handheld data entry device Exclusion criteria: Sexual dysfunctions other than HSDD, such as Sexual Aversion Disorder, Substanceinduced Sexual Dysfunction, Dyspareunia, Vaginismus, Gender Identity Disorder, Paraphilia and Sexual Dysfunction due to a General Medical Condition Partner with inadequately treated organic or psychosexual dysfunction Sexual function impaired by psychiatric disorder Sexual function impaired by gynecological disorder Major Depression Suicidal behavior or ideation Major life stress that could impair sexual function Substance abuse</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>